Slingshot members are tracking this event:
Merrimack Pharma's (TEVA) Abbreviated New Drug Application (ANDA) for Generic Version of Janssen's (JNJ) Doxorubicin Accepted for Review by FDA
Slingshot Insights Explained
Oct 31, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Abbreviated New Drug Application, Generic Version, Doxorubicin, Doxil, Liposome Injection, Ovarian Cancer, Aids-related Kaposi's Sarcoma, Multiple Myeloma